帕金森病患者对左旋多巴的反应随时间的变化。一项为期 4 年的随访研究。
Response to levodopa in Parkinson's disease over time. A 4-year follow-up study.
机构信息
CHUAC, Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain.
CHUF, Complejo Hospitalario Universitario de Ferrol, A Coruña, Spain.
出版信息
Parkinsonism Relat Disord. 2023 Nov;116:105852. doi: 10.1016/j.parkreldis.2023.105852. Epub 2023 Oct 3.
BACKGROUND AND OBJECTIVE
A good response to levodopa is a key factor to indicate device-aided therapies in people with Parkinson's disease (PwPD). The aim of the present study was to analyze the response to levodopa in PwPD with motor fluctuations followed for 4 years.
PATIENTS AND METHODS
PwPD with motor fluctuations recruited from January 2016 to November 2017 from the COPPADIS cohort and assessed annually (from baseline to 4-year follow-up) during the OFF and ON states were included in this analysis. At each visit, the Unified Parkinson's Disease Rating Scale - part III (UPDRS-III) was applied during the OFF state (without medication during the last 12 h) and during the ON state. General linear model repeated measures were used to test for changes in the mean UPDRS-III-OFF, UPDRS-III-ON, and ΔUPDRS-III (UPDRS-III-OFF - UPDRS-III-ON) between visits. Levodopa equivalent daily dose (LEDD) was included as covariate.
RESULTS
Sixty-three patients (63.94 ± 8.42 years old; 68.3% males) were included. Mean disease duration was 7.81 ± 3.64 years. From baseline to 4-year follow-up visit, a significant increase in both the UPDRS-III-OFF (from 27.98 ± 9.58 to 31.75 ± 12.39; p = 0.003) and the UPDRS-III-ON (from 15.92 ± 7.93 to 18.84 ± 8.17; p = 0.006) was observed despite the significant increase in the LEDD (from 896.35 ± 355.65 to 1085.51 ± 488.29; p = 0.003). However, no significant differences were detected between visits in the ΔUPDRS-III.
CONCLUSION
In this cohort of PwPD with motor fluctuations, the response to levodopa did not weaken after a 4-year follow-up.
背景与目的
对左旋多巴的良好反应是提示帕金森病(PD)患者进行设备辅助治疗的关键因素。本研究旨在分析经过 4 年随访的伴有运动波动的 PD 患者对左旋多巴的反应。
患者与方法
本研究纳入了 2016 年 1 月至 2017 年 11 月期间从 COPPADIS 队列中招募的伴有运动波动的 PD 患者,并在随访的第 0、1、2、3 和 4 年时进行评估(在过去 12 小时内未服用药物时处于 OFF 状态下进行评估)。在每次就诊时,应用统一帕金森病评定量表第 3 部分(UPDRS-III)在 OFF 状态(无药物)和 ON 状态下进行评分。采用重复测量的一般线性模型来检验在随访期间 UPDRS-III-OFF、UPDRS-III-ON 和 ΔUPDRS-III(UPDRS-III-OFF-UPDRS-III-ON)的平均值变化。左旋多巴等效日剂量(LEDD)作为协变量。
结果
本研究共纳入 63 例患者(63.94±8.42 岁;68.3%为男性)。平均病程为 7.81±3.64 年。从基线到 4 年随访时,UPDRS-III-OFF(从 27.98±9.58 增加到 31.75±12.39;p=0.003)和 UPDRS-III-ON(从 15.92±7.93 增加到 18.84±8.17;p=0.006)均显著增加,尽管 LEDD 显著增加(从 896.35±355.65 增加到 1085.51±488.29;p=0.003)。然而,在随访期间,ΔUPDRS-III 无显著差异。
结论
在本项研究中,经过 4 年的随访,伴有运动波动的 PD 患者对左旋多巴的反应并未减弱。